ImmunityBio
We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.
- Total raised
- $1.4B
- Latest round
- Post-IPO Equity
- Employees
- 662
About ImmunityBio
ImmunityBio is a brand dedicated to revolutionizing cancer treatment. They develop innovative therapies that target and kill the disease without compromising the immune system. Their investigational immunotherapy and cell therapy products are at the forefront of medical advancements. Through their unique approach, ImmunityBio aims to outsmart diseases such as cancer and HIV. They offer personalized immunotherapies that strengthen the patient's immune system, enabling it to effectively fight against cancerous or infected cells. By focusing on strengthening the immune system, ImmunityBio's therapies minimize the weakening effects commonly associated with traditional cancer treatments like chemotherapy and radiation therapy. In addition to their cutting-edge therapies, ImmunityBio is committed to increasing diversity in clinical trials to address healthcare disparities. They collaborate with trial investigators and researchers to discover and develop future cancer treatments. With a robust clinical pipeline, ImmunityBio is at the forefront of immunotherapy research and development. Their goal is to conquer diseases like cancer and HIV, making fear of these diseases a thing of the past.
Funding & revenue at ImmunityBio
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Total capital raised
$1.4B
3 known investors
Latest round
Post-IPO Equity · $80M
Jul 2025
Investors
Oberland CapitalPatrick Soon-ShiongNantCapital
Growth signals
How fast ImmunityBio is adding people, roles, and audience.
Employees
662
Reported band 501-1000
LinkedIn followers
35.8K
+45.8% year over year
Headcount change
- MoM
- +0.5%
- QoQ
- +1.8%
- 6mo
- +7.8%
- YoY
- +11.6%
- 2yr
- +12%
+3 people
+12 people
+48 people
+69 people
+71 people
Team composition
Where ImmunityBio concentrates its people — a read on which function a fractional leader would plug into.
By function
- Research16325%
- Operations10015%
- Quality Assurance609%
- Information Technology416%
- Sales396%
- Engineering294%
- Business Development294%
- Healthcare Services274%
By region
- United States620
- California, United States358
- Los Angeles Metropolitan Area275
- Los Angeles, CA91
- San Diego Metropolitan Area68
- San Diego, CA56
Inside ImmunityBio
What the business focuses on, where it operates, and how employees rate it.
Specialties
ImmunotherapyCancerInfectious DiseasesNatural KillerT CellVaccinesOncologyVaccineFusion ProteinsClinical TrialsCOVID-19Cell Therapy
Categories
Health DiagnosticsHealth CareOncologyTherapeuticsBiotech & PharmaceuticalsPharmaceutical and biotechnology
Markets
PRIVATENASDAQ
Offices
- 9920 Jefferson Blvd, Culver City, CA, 90232, US
- 430 Dudly Road, El Segundo, CA, 90245, US
- 1450 Infinite Dr, Louisville, CO, 80027, US
- 410 West Harrison , Seattle , WA, 98119, US
- 2750 SW 145 Ave, Miramar, FL, 33027, US
- 19 Presidential Way, Woburn, MA, 01801, US
Jobs
1
Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed August 16, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent ImmunityBio, you can claim this page to manage and enhance it.